Close
  Indian J Med Microbiol
 

Figure 2: Cytotoxicity of galactomannan fraction in phorbol myristate acetate-treated melanocytes. Cells were induced with phorbol myristate acetate (10 ng/mL) and treated with galactomannan fraction (5–150 μg/mL) and ascorbic acid standard (5–150 μg/mL). Cells without phorbol myristate acetate and sample were negative control (C–) and cells treated with phorbol myristate acetate only were positive control (C+). Data were shown as mean ± standard deviation from duplicate experiments. P < 0.05 against phorbol myristate acetate-treated cells

Figure 2: Cytotoxicity of galactomannan fraction in phorbol myristate acetate-treated melanocytes. Cells were induced with phorbol myristate acetate (10 ng/mL) and treated with galactomannan fraction (5–150 μg/mL) and ascorbic acid standard (5–150 μg/mL). Cells without phorbol myristate acetate and sample were negative control (C–) and cells treated with phorbol myristate acetate only were positive control (C+). Data were shown as mean ± standard deviation from duplicate experiments. <i>P</i> < 0.05 against phorbol myristate acetate-treated cells